登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)
ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由江苏省人民医院(南医大一附院)牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07113964,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 75 岁;性别:仅女性
登记记录的入选字段
Pathologically documented HER2-negative locally advanced or metastatic breast cancer (IHC0, IHC 1+\& IHC 2+/ISH-) that was hormone-receptor positive (i.e., estrogen-receptor positive, progesterone-receptor positive, or both) or was triple negative.
入选标准第 2 条
Has been treated with 2-4 previous therapy regimens for metastatic disease.
入选标准第 3 条
Prior treatment with immune checkpoint inhibitors (ICI) (anti-CTLA-4, anti-PD-1, anti-PD-L1, combined therapy anti-PD-1/PD-L1 with anti-CTLA-4) or olaparib for advanced disease.
排除标准第 2 条
Discontinuation of prior anti-PD-1/PD-L1/CTLA-4 therapy due to immune-related toxicity.
排除标准第 5 条
Age 18 - 75 years; Eastern Cooperative Oncology Group (ECOG) score status 0-1.
入选标准第 1 条
At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors version 1.1.
入选标准第 5 条
Has a known history of human immunodeficiency virus (HIV) infection.
排除标准第 8 条
Female subjects of reproductive/childbearing potential must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and after the last dose for at least 3 months. Negative serum or urine pregnancy test within 7 days before study enrollment, and must be a non-lactating subject.
入选标准第 8 条
Female subjects who are pregnant, lactating or plan to become pregnant during the study.
排除标准第 12 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07113964,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age 18 - 75 years; Eastern Cooperative Oncology Group (ECOG) score status 0-1. Pathologically documented HER2-negative locally advanced or metastatic breast cancer (IHC0, IHC 1+\& IHC 2+/ISH-) that was hormone-receptor positive (i.e., estrogen-receptor positive, progesterone-receptor positive, or both) or was triple negative. Has been treated with 2-4 previous therapy regimens for metastatic disease. HRD positive confirmed, known germline and/or systemic BRCA mutation status that is predicted to be deleterious or suspected deleterious allow preferential enrolment. At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors version 1.1. Has protocol-defined adequate bone marrow, renal, hepatic and blood clotting functions. A life expectancy of at least 12 weeks. Female subjects of reproductive/childbearing potential must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and after the last dose for at least 3 months. Negative serum or urine pregnancy test within 7 days before study enrollment, and must be a non-lactating subject. Volunteer to participate in this study and sign the informed consent.排除标准:Exclusion Criteria:
Has any active autoimmune disease, which may worsen when receiving immune stimulants. Prior treatment with immune checkpoint inhibitors (ICI) (anti-CTLA-4, anti-PD-1, anti-PD-L1, combined therapy anti-PD-1/PD-L1 with anti-CTLA-4) or olaparib for advanced disease. Has unresolved toxicities from previous anticancer therapy. Has uncontrolled or significant cardiovascular disease. Discontinuation of prior anti-PD-1/PD-L1/CTLA-4 therapy due to immune-related toxicity. Known history or evidence of interstitial lung disease or active non-infectious pneumonitis. Has received a live vaccine vaccination within 28 days before enrolment. Has a known history of human immunodeficiency virus (HIV) infection. Has known history of or is positive for Hepatitis B or Hepatitis C. Any severe or poorly controlled systemic disease such as poorly controlled hypertension, active bleeding susceptibility or active infection, as judged by the investigator. Has untreated or clinically active central nervous system metastases. Female subjects who are pregnant, lactating or plan to become pregnant during the study. Has any other condition that per protocol or in the opinion of the investigator is inappropriate for the study.
引自 ClinicalTrials.gov, NCT07113964, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07113964,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。